Patients are increasingly turning to tattoos instead of MedicAlert-type bracelets and pendants to alert emergency providers to their medical conditions.
The glycoprotein IIb/IIIa inhibitor tirofiban (Aggrastat) is “non-inferior” to its more expensive counterpart abciximab (ReoPro) in ST-elevation MI patients undergoing percutaneous coronary intervention.